|
|
|
|
Elevated Brain natriuretic peptide predicts mortality in interstitial lung disease
Corte TJ et al.Increased BNP levels and/or echocardiographic markers of right ventricular dysfunction were associated with increased mortality across ILD. Elevated Brain natriuretic peptide predicts mortality in interstitial lung disease.
|
|
|
Autoimmune Hepatitis Type 2 Arising in PFAPA Syndrome: Coincidences or Possible Correlations
Corte CD et al.The authors suppose that the dysregulation in innate immunity that is typical of patients with PFAPA could trigger autoimmune disorders such as autoimmune hepatitis in susceptible subjects. Autoimmune Hepatitis Type 2 Arising in PFAPA...
|
|
|
Corcept Therapeutics Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released ..
Corcept Therapeutics Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances Profile - new market report released Refer to a friend 2010-03-10 20:17:14 - Corcept Therapeutics Incorporated - Pharmaceuticals & Healthcare - Deals and Alliances...
|
|
|
Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Ac
Farhad Ravandi,* Jorge E.Cortes, Daniel Jones, Stefan Faderl, Guillermo Garcia-Manero, Marina Y. Konopleva, Susan O'Brien, Zeev Estrov, Gautam Borthakur, Deborah Thomas, Sherry R. Pierce, Mark Brandt, Anna Byrd, B. Nebiyou Bekele, Keith Pratz,...
|
|
|
Dangers of black market plastic surgery
new jersey, local news, toni yates More: Bio, News Team NEW JERSEY (WABC) -- Women around the world have paid thousands of dollars to plastic surgeons to improve their look from behind.Information on the internet about buttocks enhancement gets hundreds of...
|
|
|
Dangers of black market plastic surgery
new jersey, local news, toni yates More: Bio, News Team NEW JERSEY (WABC) -- Women around the world have paid thousands of dollars to plastic surgeons to improve their look from behind.Information on the internet about buttocks enhancement gets hundreds of...
|
|
|
Corcept Therapeutics Initiates A Phase 1 Study Of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- C
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the Phase 1 study of its next-generation...
|
|
|
Medical News: Corcept Therapeutics Initiates A Phase 1 Study Of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
News Useful Links tweetmeme_source = 'mnt_psychology'; tweetmeme_service = 'bit.ly'; Main Category: Also Included In:/ Drug Trials; Mental Health Article Date: 24 Feb 2010 - 19:00 PST printer friendly Current Article Ratings: Patient / Public: Health...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the Phase 1 study of its next-generation...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
MENLO PARK, CA (MARKET WIRE) 02/23/10 Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist -- CORT 108297
Companies mentioned in this article: Corcept Therapeutics MENLO PARK, CA -- (Marketwire) -- 02/23/10 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of...
|
|
|
Corcept Therapeutics Initiates a Phase 1 Study of Its Lead Selective Cortisol Receptor (GR-II) Antagonist CORT
MENLO PARK, CA (MARKET WIRE) 02/23/10 Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders, has begun dosing in the...
|
|
|
Skilas Launch Readiness Solution Chosen by Top 20 US Pharmaceutical Company
Skila, a leading provider of knowledge agility and stakeholder collaboration management solutions, announces that a Top-20 US pharmaceutical company has chosen Skilas Launch Readiness solution for two of its upcoming product launches.FOR IMMEDIATE RELEASE PR...
|
|
|
SkilaEURs Launch Readiness Solution Chosen by Top 20 US Pharmaceutical Company
Launch Readiness will enable the clients launch teams to follow an organized launch process and launch readiness plan for all launch related activities, as well as increase knowledge, collaboration and effectiveness of the launch teams.We are delighted to...
|
|
|
More than 400 People Turn out for European Spallation Source Industry Day
The ESS Industry Day was held in Copenhagen, Denmark.More than 400 representatives from European business and industry took part and gained information about how to get involved in the construction of the ESS. The European Spallation Source will be the...
|
|
|
Glaxo remover cinc de crema dental
WASHINGTON (AP) -- El fabricante del adhesivo para dentaduras Poligrip dejar de utilizar frmulas que contienen cinc debido a demandas que sealan que tras aos de uso excesivo caus daos neurolgicos y problemas vasculares, supuestamente incapacitando a algunos.
|
|
|
NYU Taps Cortes as Visiting Professor of Geriatric Nursing
Tara A.Cortes, PhD, RN, FAAN, joined NYU College of Nursing as the first Mathy D. Mezey Visiting Professor of Geriatric Nursing. Cortes will be working with the Hartford Institute for Geriatric Nursing and the Nurses Improving Care for...
|
